133 related articles for article (PubMed ID: 28341657)
1. Effect of fixation time on breast biomarker expression: a controlled study using cell line-derived xenografted (CDX) tumours.
Kao KR; Hasan T; Baptista A; Truong T; Gai L; Smith AC; Li S; Gonzales P; Voisey K; Eriwvo P; Power J; Denic N
J Clin Pathol; 2017 Oct; 70(10):832-837. PubMed ID: 28341657
[TBL] [Abstract][Full Text] [Related]
2. Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu.
Halilovic A; Bulte J; Jacobs Y; Braam H; van Cleef P; Schlooz-Vries M; Werner A; Boelens O; Nagtegaal I; de Wilt H; Bult P
J Clin Pathol; 2017 Sep; 70(9):781-786. PubMed ID: 28325747
[TBL] [Abstract][Full Text] [Related]
3. Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization.
Yamashita-Kashima Y; Shu S; Yorozu K; Hashizume K; Moriya Y; Fujimoto-Ouchi K; Harada N
Gastric Cancer; 2014 Oct; 17(4):638-47. PubMed ID: 24414131
[TBL] [Abstract][Full Text] [Related]
4. Estrogen, progesterone, and HER-2 receptor immunostaining in cytology: the effect of varied fixation on human breast cancer cells.
Maleki S; Dorokhova O; Sunkara J; Schlesinger K; Suhrland M; Oktay MH
Diagn Cytopathol; 2013 Oct; 41(10):864-70. PubMed ID: 23447357
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of cell-line-derived xenograft tumours as controls for immunohistochemical testing for ER and PR.
Hasan T; Carter B; Denic N; Gai L; Power J; Voisey K; Kao KR
J Clin Pathol; 2015 Sep; 68(9):746-51. PubMed ID: 26092992
[TBL] [Abstract][Full Text] [Related]
6. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
[TBL] [Abstract][Full Text] [Related]
7. The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays.
Babic A; Loftin IR; Stanislaw S; Wang M; Miller R; Warren SM; Zhang W; Lau A; Miller M; Wu P; Padilla M; Grogan TM; Pestic-Dragovich L; McElhinny AS
Methods; 2010 Dec; 52(4):287-300. PubMed ID: 20807574
[TBL] [Abstract][Full Text] [Related]
8. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
[TBL] [Abstract][Full Text] [Related]
9. Current issues in ER and HER2 testing by IHC in breast cancer.
Gown AM
Mod Pathol; 2008 May; 21 Suppl 2():S8-S15. PubMed ID: 18437174
[TBL] [Abstract][Full Text] [Related]
10. An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines.
O'Grady A; Allen D; Happerfield L; Johnson N; Provenzano E; Pinder SE; Tee L; Gu M; Kay EW
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):489-93. PubMed ID: 20661132
[TBL] [Abstract][Full Text] [Related]
11. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
12. Human epidermal growth factor receptor 2 expression in breast cancer: correlation with clinical pathological features.
Ning SF; Li JL; Luo CP; Wei CH; Lu YK; Liu HZ; Wei WE; Zhang LT
Int J Clin Exp Pathol; 2014; 7(12):8740-7. PubMed ID: 25674240
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
[TBL] [Abstract][Full Text] [Related]
14. Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer.
Moatamed NA; Nanjangud G; Pucci R; Lowe A; Shintaku IP; Shapourifar-Tehrani S; Rao N; Lu DY; Apple SK
Am J Clin Pathol; 2011 Nov; 136(5):754-61. PubMed ID: 22031314
[TBL] [Abstract][Full Text] [Related]
15. Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization.
Annaratone L; Simonetti M; Wernersson E; Marchiò C; Garnerone S; Scalzo MS; Bienko M; Chiarle R; Sapino A; Crosetto N
Oncotarget; 2017 Mar; 8(12):18680-18698. PubMed ID: 28423635
[TBL] [Abstract][Full Text] [Related]
16. [Delay in formalin fixation and HER2 testing in gastric cancer].
Zeng L; Huang J; Ma Y; Liu Y; Wei Y; Zheng Q; Ye H
Zhonghua Bing Li Xue Za Zhi; 2014 Jul; 43(7):468-72. PubMed ID: 25327797
[TBL] [Abstract][Full Text] [Related]
17. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
[TBL] [Abstract][Full Text] [Related]
18. Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization.
Lin CK; Lin WL; Chen FL; Lee MY; Kuo JF; Ruan A; Tyan YS; Chiang H; Chou MC; Han CP
Int J Gynecol Pathol; 2011 Jul; 30(4):372-9. PubMed ID: 21623202
[TBL] [Abstract][Full Text] [Related]
19. The Impact of 2013 Updated ASCO/CAP HER2 Guidelines on the Diagnosis and Management of Invasive Breast Cancer: A Single-Center Study of 1739 Cases.
Zhang X; Bleiweiss I; Jaffer S; Nayak A
Clin Breast Cancer; 2017 Oct; 17(6):486-492. PubMed ID: 28433541
[TBL] [Abstract][Full Text] [Related]
20. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
Varga Z; Noske A
PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
